Cutting-edge technology application for prostate disease management in Indonesia: implementation of Healthcare 5.0 towards Indonesia’s Golden Vision 2045

  • Agus Rizal Ardy Hariandy Hamid Medical Journal of Indonesia; Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Keywords: Commentary
Abstract viewed: 54 times
PDF downloaded: 21 times
HTML downloaded: 3 times
EPUB downloaded: 3 times

Abstract

[No abstract available]

Downloads

Download data is not yet available.

References

  1. Jayani DH. [Elderly number is projected to be almost one-fifth of Indonesia's population in 2045] [Internet]. Katadata; 2021 [cited 2023 Oct 16]. Available from: https://databoks.katadata.co.id/datapublish/2021/12/22/jumlah-lansia-diproyeksikan-hampir-seperlima-penduduk-indonesia-pada-2045. Indonesian.

  2. Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healt Longev. 2022;3(11):E754-76. https://doi.org/10.1016/S2666-7568(22)00213-6

  3. Zhang W, Cao G, Wu F, Wang Y, Liu Z, Hu H, et al. Global burden of prostate cancer and association with socioeconomic status, 1990-2019: a systematic analysis from the Global Burden of Disease Study. J Epidemiol Glob Health. 2023;13(3):407−21. https://doi.org/10.1007/s44197-023-00103-6

  4. World Health Organization. The Global Cancer Observatory. Indonesia Cancer Fact Sheet Globocan 2020 [Internet]. World Health Organization; 2020 [cited 2022 Jan 17]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf

  5. Precedence Research. Prostate cancer market size and growth 2023 to 2032 [Internet]. Precedence Research; 2023 [cited 2023 Oct 16]. Available from: https://www.precedenceresearch.com/prostate-cancer-market.

  6. do Pazo C, Webster RM. The prostate cancer drug market. Nat Rev Drug Discov. 2021;20(9):663-4. https://doi.org/10.1038/d41573-021-00111-w

  7. Gomathi L, Mishra AK, Tyagi AK. Industry 5.0 for Healthcare 5.0: opportunities, challenges and future research possibilities. 2023 7th International Conference on Trends in Electronics and Informatics (ICOEI); 2023; Tirunelveli, India. p. 204-13. https://doi.org/10.1109/ICOEI56765.2023.10125660

  8. Luvhengo TE, Kgoebane-Maseko M, Phakathi BP, Magangane P, Mtshali N, Demetriou D, et al. Society 5.0 and quality multidisciplinary care of malignant solid tumors in low- and middle-income settings. In: Dlamini Z, editor. Society 50 and next generation healthcare [Internet]. Cham: Springer; 2023. p. 51-77. Available from: https://doi.org/10.1007/978-3-031-36461-7_3

  9. Ministry of Public Works and Housing. [SIMANTU Indonesia's vision 2045] [Internet]. [cited 2023 Oct 20]. Available from: https://simantu.pu.go.id/content/?id=502. Indonesian.

  10. The Urology Group. Holmium laser enucleation of the prostate (HoLEP) for BPH [Internet]. [cited 2023 Oct 25]. Available from: https://www.urologygroup.com/condition/holep/.

  11. Sağlam R. Orientation for HOLEP operation. Prostate can be enucleated from its capsule and push into the bladder [Internet]. 2017 [cited 2023 Oct 25]. Available from: https://twitter.com/remzisaglam47/status/830521549342007296.

  12. Huynh LM, Ahlering TE. Robot-assisted radical prostatectomy: a step-by-step guide. J Endourol. 2018;32(S1):S28−32. https://doi.org/10.1089/end.2017.0723

  13. Xu H, Lasso A, Vikal S, Guion P, Krieger A, Kaushal A, et al. MRI-guided robotic prostate biopsy: a clinical accuracy validation. Med Image Comput Comput Assist Interv. 2010;13(Pt 3):383−91. https://doi.org/10.1007/978-3-642-15711-0_48

  14. Moreira P, Patel N, Wartenberg M, Li G, Tuncali K, Heffter T, et al. Evaluation of robot-assisted MRI-guided prostate biopsy: needle path analysis during clinical trials. Phys Med Biol. 2018;63(20):20NT02. https://doi.org/10.1088/1361-6560/aae214

  15. Hamid AR, Wibowo PK. Effectiveness of robotic prostate biopsy in detecting prostate cancer. Unpublished.

  16. Wetterauer C, Trotsenko P, Matthias MO, Breit C, Keller N, Meyer A, et al. Diagnostic accuracy and clinical implications of robotic assisted MRI-US fusion guided target saturation biopsy of the prostate. Sci Rep. 2021;11(1):20250. https://doi.org/10.1038/s41598-021-99854-0

  17. Precedence Research. Surgical robotics market size to reach USD 36.37 bn by 2032 [Internet]. Precedence Research; 2023 [cited 2023 Oct 29]. Available from: https://www.precedenceresearch.com/surgical-robotics-market.

  18. Mohan A, Wara UU, Arshad Shaikh MT, Rahman RM, Zaidi ZA. Telesurgery and robotics: an improved and efficient era. Cureus. 2021;13(3):e14124. https://doi.org/10.7759/cureus.14124

  19. Soni T, Gupta D, Uppal M, Juneja S. Explicability of artificial intelligence in Healthcare 5.0. In: 2023 International Conference on Artificial Intelligence and Smart Communication (AISC); 2023; Greater Noida, India. p. 1256-61. https://doi.org/10.1109/AISC56616.2023.10085222

  20. Bajwa J, Munir U, Nori A, Williams B. Artificial intelligence in healthcare: transforming the practice of medicine. Future Healthc J. 2021;8(2):e188−94. https://doi.org/10.7861/fhj.2021-0095

  21. Safriadi F, Umbas R, Danarto, Hakim L, Warli SM, Hamid AR, et al. [Prostate cancer treatment guide]. Jakarta: The Indonesian Association of Urologists; 2022. Indonesian.

  22. Keerthy AS, Manju Priya S. Artificial intelligence in healthcare databases. In: Suresh A, Paiva S, editors. Deep learning and edge computing solutions for high-performance computing [Internet]. Cham: Springer; 2021. p. 19-34. Available from: https://doi.org/10.1007/978-3-030-60265-9_2. https://doi.org/10.1007/978-3-030-60265-9_2

  23. Yuri P, Wangge G, Abshari F, Satjakoesoemah AI, Perdana NR, Wijaya CD, et al. Indonesian prostate cancer risk calculator (IPCRC): an application for predicting prostate cancer risk (a multicenter study). Acta Med Indones. 2015;47(2):95-103.

  24. Akaza H, Hirao Y, Kim CS, Oya M, Ozono S, Ye D, et al. Asia prostate cancer study (A-CaP Study) launch symposium. Prostate Int. 2016;4(3):88−96. https://doi.org/10.1016/j.prnil.2016.03.001

  25. Hulisnaini H, Juliangrace S. [Transformation of Pedulilindungi into Satu Sehat] [Internet]. 2023;9. Indonesian.

  26. Mbunge E, Muchemwa B, Jiyane S, Batani J. Sensors and healthcare 5.0: transformative shift in virtual care through emerging digital health technologies. Global Health J. 2021;5(4):169-77. https://doi.org/10.1016/j.glohj.2021.11.008

  27. Sciarra A, Gentile V, Panebianco V. Multidisciplinary management of prostate cancer: how and why. Am J Clin Exp Urol. 2013;1(1):12−7. https://doi.org/10.1016/S1569-9056(13)60506-0

  28. Hoinville L, Taylor C, Zasada M, Warner R, Pottle E, Green J. Improving the effectiveness of cancer multidisciplinary team meetings: analysis of a national survey of MDT members' opinions about streamlining patient discussions. BMJ Open Qual. 2019;8(2):e000631. https://doi.org/10.1136/bmjoq-2019-000631

  29. Selby P, Popescu R, Lawler M, Butcher H, Costa A. The value and future developments of multidisciplinary team cancer care. Am Soc Clin Oncol Educ Book. 2019;39:332−40. https://doi.org/10.1200/EDBK_236857

  30. J AV, Sankar K, Kumar AS, Sridevi M, Prasad DD. An IOT-based computational intelligence model to perform gene analytics in paternity testing and comparison for health 4.0. J Theor Appl Inf Technol. 2023;101(14):5781-96.

  31. ESMO 2019 Congress. OncologyPRO [Internet]. [cited 2023 Oct 23]. Available from: https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/Central-prospective-detection-of-homologousrecombination-repair-gene-mutations-HRRm-in-tumour-tissue-from-4000-men-with-metastatic-castration-resistant-prostate-cancermCRPC-screened-for-the-PROfound-study.

  32. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215−28. Erratum in: Cell. 2015;162(2):454. https://doi.org/10.1016/j.cell.2015.05.001

  33. Takeshima H, Ushijima T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. NPJ Precis Oncol. 2019;3(7). https://doi.org/10.1038/s41698-019-0079-0

  34. Chiu PK, Lee EK, Chan MT, Chan WH, Cheung MH, Lam MH, et al. Genetic testing and its clinical application in prostate cancer management: consensus statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology. Front Oncol. 2022;12:962958. https://doi.org/10.3389/fonc.2022.962958

  35. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091−102. https://doi.org/10.1056/NEJMoa1911440

  36. Guest NS, Horne J, Vanderhout SM, El-Sohemy A. Sport nutrigenomics: personalized nutrition for athletic performance. Front Nutr. 2019;6:8. https://doi.org/10.3389/fnut.2019.00008

  37. Vietri MT, D'Elia G, Caliendo G, Resse M, Casamassimi A, Passariello L, et al. Hereditary Prostate cancer: genes related, target therapy and prevention. Int J Mol Sci. 2021;22(7):3753. https://doi.org/10.3390/ijms22073753

  38. Idris F. [2019 program management report and financial report] [Internet]. 2020 [cited 2023 Feb 23]. Available from: https://www.bpjskesehatan.go.id/bpjs/arsip/view/1520. Indonesian.

  39. Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807−23. https://doi.org/10.1177/1557988318798279

  40. Alodokter. [Cost of PSA (prostate-specific antigen) examination at - best hospital] [Internet]. [cited 2023 Oct 24]. Available from: https://www.alodokter.com/cari-rumah-sakit/andrologi/pemeriksaan-psa-prostatspesifik-antigen. Indonesian.

  41. Central Bureau of Statistics. [Population number of SP2020 results men by region, age group (people)] [Internet]. 2020 [cited 2023 Feb 23]. Available from: https://www.bps.go.id/indicator/12/2135/1/jumlahpenduduk-hasil-sp2020-laki-laki-menurut-wilayah-kelompok-umur.html. Indonesian.

  42. Rokom. [Series of health transformations by Minister of Health Budi] [Internet]. Sehat Negeriku: Indonesian Ministry of Health Communications & Public Services Bureau; 2022 [cited 2023 Oct 26]. Available from: https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20220531/5640005/deretan-transformasi-kesehatan-oleh-menkes-budi/. Indonesian.

  43. Armandari I, Hamid AR, Verhaegh G, Schalken J. Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. Prostate Int. 2014;2(3):105−13. https://doi.org/10.12954/PI.14063

  44. Cai Y, Zhang S, Dong C, Yang J, Ma T, Zhang H, et al. Lateral flow immunoassay based on gold magnetic nanoparticles for the protein quantitative detection: prostate-specific antigen. Anal Biochem. 2021;627:114265. https://doi.org/10.1016/j.ab.2021.114265

  45. Assefa A, Germossa GN, Ayenew M, Bedada GB. Awareness of prostate cancer and its associated factors among men 40 years of age and older in Mizan Aman town, Bench Sheko zone, Southern Nations, Nationalities, and Peoples' Region, South West Ethiopia, 2019. Front Oncol. 2022;12:976810. https://doi.org/10.3389/fonc.2022.976810

  46. Directorate of Prevention and Control of Non-Communicable Diseases, Indonesian Ministry of Health. [Remember CERDIK to prevent the risk ofvarious non-communicable diseases] [Internet]. Directorate of Prevention and Control of Non-Communicable Diseases, Indonesian Ministry of Health; 2018 [cited 2023 Oct 25]. Available from: https://p2ptm.kemkes.go.id/infographic/ingat-cerdik-untuk-mencegah-risiko-dari-berbagai-penyakit-tidak-menular. Indonesian.

  47. Turkan S, Doğan F, Ekmekçioğlu O, Çolak A, Kalkan M, Şahin Ç. The level of knowledge and awareness about prostate cancer in the Turkish male and the relevant effective factors. Turk J Urol. 2016;42(3):134−9. https://doi.org/10.5152/tud.2016.90235

  48. Olsen TA, Filson CP, Richards TB, Ekwueme DU, Howard DH. The cost of metastatic prostate cancer in the United States. Urol Pract. 2023;10(1):41−7. https://doi.org/10.1097/UPJ.0000000000000363

  49. Department of Urology, Faculty of Medicine, Universitas Indonesia. [PCAM 2021 week 1: early detection and various treatments for prostate cancer] [Internet]. 2021 [cited 2023 Oct 25]. Available from: https://www.youtube.com/watch?v=0w1kpTackRc. Indonesian.

  50. Alqudah MA, Al-Samman R, Matalgah O, Abu Farhah R. Early detection of prostate cancer: self-reported knowledge and attitude of physicians in Jordan. Inquiry. 2022;59:469580221095822. https://doi.org/10.1177/00469580221095822

  51. Jain AK. Impact factor: measure of quality of research publication. Indian J Orthop. 2011;45(4):289−90. https://doi.org/10.4103/0019-5413.82330

Published
2024-07-24
How to Cite
1.
Hamid ARAH. Cutting-edge technology application for prostate disease management in Indonesia: implementation of Healthcare 5.0 towards Indonesia’s Golden Vision 2045. Med J Indones [Internet]. 2024Jul.24 [cited 2024Jul.27];33(2):63-9. Available from: https://mji.ui.ac.id/journal/index.php/mji/article/view/7688
Section
Commentary